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Galectins constitute an evolutionary conserved family that bind to β-galactosides. Increasing evidence shows that
galectins are involved in many fundamental biological processes such as cellular communication, inflammation,
differentiation and apoptosis. Changes in galectin-3 (Gal-3) expression are commonly seen in cancer and
pre-cancerous conditions, and Gal-3 may be involved in the regulation of diverse cancer cell activities that
contribute to tumourigenesis, cancer progression and metastasis. In addition, Gal-3 is a pro-inflammatory regulator in
rheumatoid arthritis. Gal-3 has been shown to be involved in many aspects in allergic inflammation, such as eosinophil
recruitment, airway remodeling, development of a Th2 phenotype as well as increased expression of inflammatory
mediators. In an in vivo model it was shown that bronchoalveolar lavage (BAL) fluid from ovalbumin-challenged
mice contained significantly higher levels of Gal-3 compared to control mice. The molecular mechanisms of Gal-3
in human asthma have not been fully elucidated. This review will focus on what is known about the Gal-3 and its
role in the pathophysiological mechanisms of asthma to evaluate the potential of Gal-3 as a biomarker and
therapeutic target of asthma.
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Galectins are a family of evolutionary conserved animal
lectins that bind to β-galactosides. They are ubiquitous
in mammals and other vertebrate taxa, invertebrates, and
fungi [1,2]. First described in the 1970s, galectins are in-
volved in the recognition of carbohydrate ligands during
embryogenesis [3]. In recent years, galectins have been
shown to have significant immunoregulatory activities,
such as cell differentiation, tissue organization, and the
regulation of immune homeostasis [4,5]. Galectins have
been shown to bind glycans on the surface of bacteria, vi-
ruses, protozoa and fungi, which indicates a potential role
in the recognition of pathogens [6,7]. So far, 15 galectin
members have been identified in a wide variety of tissues
[4,8]. All galectins share close sequence homology in their
carbohydrate recognition domain (CRD) but exhibit differ-
ent affinities for different saccharide ligands [9]. Galectins
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reproduction in any medium, provided the oractivity (Figure 1), which accounts for their ability to
cross-link cell surface glycoproteins. Based on structural
differences, the galectins can be classified into three dis-
tinct subgroups [Figure 1]. Prototypic galectins (galectin-
1,-2,-5, -7, -10, -11, -13, -14, and −15) have one CRD and
are capable of homodimerization. Tandem repeat type
galectins (galectin-4, -6, -8, -9, and −12) consist of two dis-
tinct CRDs which are joined by a linker of up to 70 amino
acids and have differential affinity for carbohydrates. Gal-3
is a unique member of chimera type galectins and exhibits
both extracellular and intracellular functions. The protein
contains a single CRD with an extended N-terminus which
plays a role in protein oligomerization and may partici-
pate in the interaction with other intracellular proteins
[4,10-12]. This means that Gal-3 can interact with both
carbohydrates and proteins.
Gal-3 was first discovered as an IgE-binding protein,
and characterized as a 32 kDa antigen (Mac-2) on the
surface of murine macrophages [14]. Gal-3 is widely dis-
tributed and localizes to the extracellular space, cyto-
plasmic or nuclear regions. Like other members of the
galectin family, Gal-3 does not possess a secretion signal
peptide that would direct transport through the classical. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The structure and classification of different members of the galectin family. Adapted from [13].
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[10]. At low concentrations, Gal-3 is a monomer, or can
potentially form oligomers but only upon binding to
multivalent saccharides, a feature that imparts great
flexibility on Gal-3. As a result of the activation of sig-
naling pathways involved in the modulation of a number
of cellular processes, Gal-3 can crosslink cell surface re-
ceptors, leading to the formation of lattices that cluster
these ligands into lipid raft micro-domains [15-18].
These cellular processes include cell-cell adhesion, pro-
liferation, differentiation, apoptosis, and cytokine secre-
tion. Through protein-protein interactions, Gal-3 can
react with many extracellular and/or intracellular pro-
teins. This can be done in a carbohydrate dependent or
independent manner respectively [19-23].
In recent decades, the literature on Gal-3 has been
rapidly growing. The reason generating this increasing
interest relates to the broad range of functions displayed
by Gal-3. It has now been found that Gal-3 is related to
the physiopathology of multiple diseases (Table 1). Gal-3
has been known to be involved in many aspects in
asthma, such as eosinophil recruitment [24,25], airway
remodeling, development of a Th2 phenotype as well as
increased expression of inflammatory mediators [26].
This review will focus on what is known about the Gal-3
and its role in the pathophysiological mechanisms in
asthma.
Gal-3 in inflammation
Asthma is a chronic inflammatory respiratory disease charac-
terized by airway inflammation, airway hyperresponsiveness(AHR) and reversible airway obstruction [34]. Treatments
targeting eosinophilic inflammation in asthma are able to
reduce asthma exacerbations, however the inflammatory
mechanisms leading to asthma symptoms and AHR in the
absence of sputum eosinophilia is poorly understood. Gal-
3 is potentially relevant in the pathogenesis of inflamma-
tion in asthma and its phenotypes.Gal-3 expression in the inflammatory setting
A variety of tissues and cell types express Gal-3 under
basal conditions, including epithelial cells, dendritic cells,
macrophages and neutrophils [11,35,36]. However, the
pattern of expression can be modulated in the inflam-
matory setting. In vivo, an increase in the extracellular
concentration of Gal-3 has been measured in the in-
flammatory setting in animal models. Bronchoalveolar
lavage (BAL) fluid from ovalbumin (OVA) challenged
mice contained significantly higher levels of Gal-3 com-
pared to control mice [24], similar to the results from
mice infected with Streptococcus pneumonia [37]. Ele-
vated levels of Gal-3 were also detected in prion-
infected brain tissue [38], and in synovial tissue and
serum from patients with rheumatoid arthritis (RA)
[28]. In RA, serum Gal-3 levels were increased further
in uncontrolled disease. In human asthma, highly vari-
able Gal-3 expression was detected on both sputum
macrophages and neutrophils by flow cytometry, and al-
though it tended to be lower in asthmatic patients com-
pared to healthy controls, this difference did not reach
statistical significance [39].
Table 1 The levels of serum Gal-3 in different patients
Disease Method and assay Level in blood (ng/ml) Comments
Heart failure ELISA (BG Medicine,
Waltham, USA).
Decrease in left ventricular systolic
function (LVEDV): 14.7(12.8-18.2);
stable LVEDV: 17.9(13.7-22);
increase in LVEDV: 19(14.9-24.4).
Patients were divided into three groups
according to the change in LVEDV: decrease
in LVEDV > 8%, stable LVEDV (−8–8%) and an
increase in LVEDV> 8%. Plasma Gal-3 is associated
with left ventricular remodeling determined by
serial echocardiography and predicts long-term
mortality in patients with severe chronic heart
failure [27].
Rheumatoid arthritis (RA) ELISA (R&D Systems,
Minneapolis, USA).
Gal-3 was elevated in RA serum and
synovial fluids. In RA, serum Gal-3
correlated with C-reactive protein levels.
Gal-3 is not only involved in inflammation,









Serum levels of Gal-3 are highest in active
JIA children, followed by inactive disease
and controls [29].
Behçet’s disease (BD) ELISA (R&D Systems,
Minneapolis, USA).
Active BD patients: 13.08 ± 1.53;
inactive BD patients: 8.08 ± 0.71;
healthy controls: 7.59 ± 0.48.
Active BD patients had significantly higher
levels of serum Gal-3 than inactive patients
and controls [30].




Serum Gal-3 levels were significantly higher
in subpopulations of patients having each
type of tumor [31].
ELISA (Bender MedSystems,
Vienna, Austria).
Controls: 3.07 ± 0.69; Colorectal
cancer: 6.81 ± 4.07






Serum Gal-3 concentration of the bladder
cancer patients was higher than that of
controls [33].




Gal-3 in asthma serum was lower than
that of controls (not published).
Data are expressed as mean ± SD or median (IQR).
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Gal-3 are enhanced after several different stimuli. In-
creased Gal-3 protein was detected in muscle endothe-
lium by immunohistology accompanied by elevated Gal-3
in the serum of mice fed with a diet containing 60% fat
calories [40]. Elevated levels of Gal-3 were also mea-
sured in both alveolar vascular endothelial cells and al-
veolar macrophages, indicating both cell types as a
potential source of the elevated Gal-3 [41]. In human
endothelium, Gal-3 is regulated at the protein level in
response to IL-1β, and at the mRNA level in response to
advanced glycation end products casein (AGE-Cas) [42].
These findings are consistent with upregulation of Gal-3
with immune activation, since dietary fat and IL-1β are in-
volved in innate immune activation. Furthermore, macro-
phages in the BAL of OVA challenged mice expressed
large amounts of Gal-3, and these were the major cell type
that contained Gal-3 [24]. In addition, the increased level
of Gal-3 has also been detected on the surface of neutro-
phils [43], eosinophils [44], mast cell, monocytes and
lymphocytes [25].
Regulation of leukocyte trafficking and activation
An increasing number of studies has demonstrated that
Gal-3 plays a critical role in the process of leukocyte
trafficking, activation and cytokine release. One facet ofinflammation where Gal-3 appears to have beneficial ef-
fects is phagocytosis, which is necessary to clear patho-
gens, foreign bodies and cellular debris, thus allowing
inflammation to resolve. Gal-3 can also regulate cell
apoptosis from both inside and outside the cell (Figure 2)
[45,46]. Moreover, Gal-3 is a unique member of the family
with both anti- and pro-apoptotic activity [47]. Cyto-
plasmic Gal-3 binding to Fas would inhibit apoptosis by
localising to the mitochondrial membrane to maintain
mitochondrial membrane integrity and preventing the
cytochrome c release [45,48-50]. In contrast, extracellular
Gal-3 directly induces T cell death in a carbohydrate-
dependent manner by binding to its cell surface receptors,
such as CD7, CD29 [46].
Macrophage/monocyte
Gal-3, as a chemoattractant and adhesion factor, plays
an important role in the trafficking of monocytes and
macrophages. In vitro, recombinant human Gal-3 in-
duces monocyte/macrophage migration. These processes
could be inhibited by addition of lactose, specific mAb,
and the C-terminal domain fragment. In addition, Gal-3
causes Ca2+ influx in monocytes, and both the chemo-
tactic effect and the induction of Ca2+ influx involve a
pertussis toxin-sensitive pathway, which suggests a role
for G protein-coupled receptors [52]. In vivo, Gal-3-
Figure 2 The intracellular and extracellular functions of galectin-3. The blue arrow indicates positive effects, the T-shaped end indicates
negative effects. LPS, lipopolysaccharide; TLR, Toll-like receptor; IL, interleukin; Th, helper T cell; PI3K, phosphatidylinositol 3-kinase; G-3, galectin-3;
PTX, Pertussis toxin; BCL-2, B-cell lymphoma-2; MAPK, Mitogen-activated protein kinase. Adapted from [26,51-53].
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peritoneal macrophages and granulocytes compared with
wild-type mice when treated with thioglycolate i.p. [54,55].
Gal-3 can activate monocytes/macrophages through its
lectin function (Figure 2). In vitro, Gal-3 (ie, approxi-
mately 10–100 nM) can induce optimal superoxide release
from monocytes [52,56] and promote the uptake of apop-
totic neutrophils from monocyte derived macrophages
[57]. Conversely, Gal-3 deficient macrophages exhibited
reduced phagocytosis of IgG-opsonized erythrocytes and
apoptotic thymocytes in vitro compared to wild type cells.
In addition, Gal-3−/− mice showed attenuated phagocytic
clearance of apoptotic thymocytes by peritoneal macro-
phages in vivo. These mice also exhibited reduced IgG-
mediated phagocytosis of erythrocytes by Kupffer cells in
a murine model of autoimmune hemolytic anemia [58].
This is further corroborated by in vitro studies in which
Gal-3 null macrophages demonstrate reduced phagocyt-
osis of apoptotic neutrophils [37].Alternative macrophage activation has been implicated
in asthma [59-61]. Gal-3 has a property of negative regu-
lation of LPS function, which protects the host from
endotoxin shock while increasing Salmonella survival. In
contrast, blocking Gal-3 binding sites enhanced LPS-
induced inflammatory cytokine expression by wild-type
macrophages [62]. Furthermore, Gal-3 deficient mice in-
fected with Toxoplasma gondii, produced larger amounts
of IL-12, and induced Th1 polarized immune response
(Figure 2) [63]. The disruption of the Gal-3 gene specif-
ically restrains IL-4/13-induced alternative macrophage
activation without affecting IFN-γ/LPS-induced classical
activation or IL-10-induced deactivation. This results
were supported by other recent studies [64,65].
Neutrophil
Gal-3 promotes the adhesion of human neutrophils
[66,67]. Furthermore, in an in vivo streptococcal pneumo-
nia mouse model, neutrophil extravasation was closely
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which was β2-integrin independent [67]. In peripheral
blood neutrophils, cross-linking of CD66b, a candidate re-
ceptor for Gal-3, mediates the release of interleukin-8
from intracellular storage [68], the most potent chemo-
attractant for neutrophils. Some other results, in line
with a decreased cellular infiltrate observed in numer-
ous in vivo models of inflammation performed in Gal-3
knockout mice, have provided more evidence for a role
for this protein in mediating leukocyte recruitment dur-
ing an inflammatory response [41,55,63,69]. One of the
possible explanations of the trafficking mechanisms is
that the cross-linking of neutrophil CD66a and/or
CD66b, the functional Gal-3 receptors, resulted in in-
creased adhesion of the neutrophils to endothelial cells
[68,70]. This hypothesis has been confirmed by the ob-
servation through confocal microscopy recently [71].
Concomitantly, Gal-3 can also activate neutrophils and
enhance their phagocytic capabilities. Recombinant hu-
man Gal-3 could enhance human neutrophils to release
superoxide through recognition of special cell surface
glycoproteins. This activation is dose-dependent and the
lectin property of Gal-3 is intrinsic to its carboxyl-
terminal domain. Lactose could inhibit this process [72].
In addition, Gal-3 can also increase L-selectin shedding
and interleukin-8 production in naïve and primed neu-
trophils. These activities required the presence of the C-
terminal lectin domain and the N-terminal nonlectin
domain of Gal-3. On the other hand, after Gal-3 binds
to primed neutrophils, the cells can cleave Gal-3, mainly
through elastase, which damages the N-terminal domain
of Gal-3 [73].
In vivo Gal-3−/− mice develop more severe pneumo-
nia after infection with S. pneumoniae, as demonstrated
by increased bacteremia and lung damage compared to
wild-type mice. Gal-3 reduces the severity of pneumococ-
cal pneumonia in part by augmenting neutrophil phago-
cytosis of bacteria and delaying neutrophil apoptosis
[37]. The mechanism of the increased phagocytosis of
neutrophils by Gal-3 may be through the MAPK path-
way and CD66 surface expression [Figure 2]. Disruption
of this signaling pathway abrogated Gal-3 mediated
modulation of neutrophil degranulation and phagocy-
tosis [70,74].
Eosinophils
In vitro, recombinant human Gal-3 can directly increase
rolling and adhesion of eosinophils from allergic donors
in an α-4 integrin-dependent manner, with an effect
comparable to that evoked by vascular cell adhesion
molecule (VCAM)-1. These activities could be inhibited
by specific Gal-3 mAbs as well as lactose [44]. Further-
more, CD66b, as an activation marker for human granu-
locytes, engaged by mAb or Gal-3, activated a Src kinasefamily molecule and resulted in cellular adhesion, super-
oxide production, and degranulation of eosinophils. Dis-
ruption of CD66b inhibited the adhesion and activation
of eosinophils [53]. In vivo studies in Gal-3 knockout
mice exhibited significantly lower eosinophil infiltration,
serum IgE and IL-4 (Th2 cytokine) levels compared with
wild type counterparts. This may indicate a direct effect
for Gal-3 on eosinophil trafficking or suggest that Gal-3
is critical for the development of inflammatory Th2 re-
sponses. In its absence, mice develop a Th1-polarized
response [25].
In contrast to these experiments, intratracheal instillation
of plasmid DNA encoding Gal-3 in a OVA challenged-rat
model led to normalization of the eosinophil and T cell
count in BALF and that there was a strong concomitant
inhibition of IL-5 mRNA in the lungs [75]. Twelve
weeks after the first intranasal antigen instillation in
chronically asthmatic mice, treatment with the Gal-3
gene led to an improvement in the eosinophil count and
the normalization of hyperresponsiveness to methacho-
line. Concomitantly, this treatment resulted in an im-
provement in mucus secretion and subepithelial fibrosis
in the chronically asthmatic mice, with a quantitatively
measured reduction in lung collagen, a prominent fea-
ture of airway remodeling [76]. Similarly, treatment of
chronic asthmatic mice with gene therapy using plasmid
encoding Gal-3 led to inhibition of suppressor of cyto-
kine signaling (SOCS) proteins 1 and 3, which led to an
improvement in Th2 allergic inflammation [77]. There-
fore, these results indicate that treatment with a plasmid
encoding Gal-3 may not exactly reproduce the function
of endogenous Gal-3, possibly because the protein may
be expressed differently in the cells or tissues, in the intra-
versus extra-cellular modes of action, and in monomer or
polymer between mice expressing a transgene and wild-
type mice.Other cells
Gal-3 also regulates the migratory pattern of dendritic
cells (DCs). Gal-3 deficient DCs exhibited defective
chemotaxis. Moreover, exogenous Gal-3 displays the ac-
tivation of mast cells, such as mediator release [78,79],
and the increased apoptosis of mast cells [80]. Gal-3 de-
ficient mast cells showed a significantly lower amount of
histamine, the cytokine IL-4, expression of IgE receptor
and passive cutaneous anaphylaxis reactions [81].
In T cells, Gal-3 inhibits apoptosis by interacting with
Bc1-2 in a lactose-inhibitable manner [45], and is neces-
sary for IL-2 dependent cell growth [82]. Conversely,
extracellular Gal-3 directly induces death of human thy-
mocytes and T cells by binding to T cell surface glyco-
protein receptors, such as CD7, CD29, CD43, CD45 and
CD71 [83-88].
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In a murine model of asthma treated with OVA, Gal-
3+/+ mice developed significantly enhanced allergic
airway inflammation and AHR. Firstly, Gal-3 expression
was significantly elevated in the airways of Gal-3+/+ mice,
not only in the peribronchial inflammatory cells, but
also in the fluid lining the airways as well. Secondly,
Gal-3+/+ mice exhibit significantly elevated allergic air-
way inflammation, with an increased number of eosino-
phils compared with similarly treated Gal-3−/−. Thirdly,
Gal-3−/− mice exhibited lower goblet cell metaplasia
compared to Gal-3+/+ mice. Fourthly, Gal-3+/+ mice
exhibited higher serum IgE levels than similarly treated
Gal-3−/− mice. Fifthly, Gal-3 null mice display a lower Th2
response but a higher Th1 response. Finally, Gal-3+/+ mice
manifest significantly higher airway responsiveness to
methacholine compared to Gal-3−/− mice [24,89]. Fur-
thermore, bone marrow derived mast cells (BMMC)
from Gal-3 deficient mice not only secreted significantly
lower levels of histamine and IL-4, but also exhibited lower
expression of IgE receptor and reduced passive cutaneous
anaphylaxis reactions compared with Gal-3+/+ BMMC. In
addition, Gal-3−/− BMMC contained a significantly lower
basal level of JNK1 protein than Gal-3+/+ BMMC, which
is probably responsible for the lower IL-4 expression [81].
In a mouse model of chronic allergic airway inflammation
exposed to OVA for 12 weeks, Gal-3−/− mice displayed
significantly lower airway inflammatory responses than
did wild-type mice, and lower amounts of airway remodel-
ing [26].
Gal-3 in human asthma
The inflammatory response in asthma shows hetero-
geneity, which involves many cells and cellular elements
[90]. Recognizing the different inflammatory phenotypes
within asthma is important for understanding the under-
lying disease processes. The different inflammatory pheno-
types are also clinically relevant due to potentially differing
responses to therapeutic interventions. An important clas-
sification of asthma has been performed by Simpson JL,
et al., in which asthmatic subjects were classified into four
groups based on the presence of neutrophils and eosino-
phils using the 95th percentile from the healthy control
subjects as a cut-off point [91]. This resulted in four
inflammatory subtypes, including neutrophilic asthma,
eosinophilic asthma, mixed granulocytic asthma and pau-
cigranulocytic asthma. Recent years, many studies have
demonstrated the distinct mechanisms of these subgroups,
which are important because each subtype has a distinct
mechanism and differential responses to therapy [92-98].
The mechanisms of eosinophilic asthma involve activation
of Th2 pathways, typically by allergen, and release of Th2
cytokines, such as IL-4, 5, 9 and 13. Bronchial biopsiesfrom these patients show infiltration with eosinophils, ac-
tivated mast cells, and T cells that are predominantly Th2
cells [99].
However, the mechanisms of non-eosinophilic asthma
are different from that of eosinophilic asthma. The neutro-
philic form of asthma appears to be driven by infection and
pollutant activation of innate immune responses, leading to
active IL-1β secretion via TLR and NLRP3 inflammasome
activation [100,101].
It is likely that Gal-3 might be important in non-
eosinophilic forms of asthma. In murine models, exogen-
ous Gal-3 has been linked to more severe AHR [24,26],
but this effect is associated with down regulation of IL-5
gene expression after the treatment with plasmid encod-
ing Gal-3 [75,76] and therefore the presence of non-
eosinophilic airways inflammation. While it is unknown if
these kinds of experiments represent the function of en-
dogenous Gal-3 these initially paradoxical effects (more
AHR and less Th2 inflammation) can be explained in the
context of an inflammatory phenotype, which displays the
suppressed Th2 cytokines, and persistent AHR indicates a
non-eosinophilic phenotype. Consistent with this, Gal-3 is
present on sputum macrophages and neutrophils in
asthma [39]. So far, studies of the level of Gal-3 in human
asthma have not analyzed data by inflammatory pheno-
type. Available data only shows reduced Gal-3 gene ex-
pression in asthmatic sputum cells [39]. So, there is a need
to elucidate how Gal-3 is involved in the mechanisms of
asthma phenotypes.Conclusion
As a multifunctional protein widely expressed by many
types of inflammatory cells, Gal-3 overexpression and
change of inter- and sub-cellular localization are com-
monly seen in various types of inflammatory cells.
Growing evidence has shown that Gal-3, first discovered
as an IgE-binding protein, is an important regulator of
inflammatory cell infiltration, activation, and clearance.
Recent studies of the murine models using Gal-3 gene
transfer indicate that Gal-3 is anti-inflammatory, however
these results might not represent the effect of endogenous
Gal-3. In fact, a large number of in in vivo and in vitro
studies suggest the Gal-3 is pro-inflammatory. This per-
plexing paradox may be explained by considering the het-
erogeneity of airway inflammation in asthma and the
specific effects of Gal-3 as a mechanism of noneosinophi-
lic forms of asthma. At present there are limited data
available for levels and function of Gal-3 in human asthma
or chronic obstructive pulmonary disease. Therefore, tar-
geting the actions of Gal-3 might elucidate underlying
molecular mechanisms of asthma and represent a promi-
sing therapeutic strategy for the development of effective
therapeutic agents for asthma treatment.
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